 eYugoslavia.com | Galectin plans clinical trials in first quarter 2013 Mass High Tech The company has selected GR-MD-02, a novel galectin inhibitor, as its lead candidate for NASH, a disease affecting 9 to 15 million Americans, with the only treatment being liver transplantation. “Patients who undergo liver transplantation for advanced ... GALECTIN THERAPEUTICS INC : Galectin Therapeutics Planning Clinical Trials ... |
